Scarica l'app Stockscreener
4.44
3.02%
0.13
Precedente Chiudi:
$4.31
Aprire:
$4.3
Volume 24 ore:
18,052
Relative Volume:
0.39
Capitalizzazione di mercato:
$31.49M
Reddito:
-
Utile/perdita netta:
$-101.87M
Rapporto P/E:
-3.1489
EPS:
-1.41
Flusso di cassa netto:
$-83.46M
1 W Prestazione:
+3.26%
1M Prestazione:
+0.00%
6M Prestazione:
-31.48%
1 anno Prestazione:
-33.53%
Intervallo 1D:
$4.30
$4.44
Intervallo di 1 settimana:
$4.2701
$4.616
Portata 52W:
$3.6201
$9.18
Kezar Life Sciences Inc Stock (KZR) Company Profile
Nome
Kezar Life Sciences Inc
Settore
Industria
Telefono
650-822-5600
Indirizzo
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta KZR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
4.43 | 31.49M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.15 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.48 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.65 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.72 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-11 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2018-07-16 | Iniziato | Jefferies | Buy |
| 2018-07-16 | Iniziato | Wells Fargo | Outperform |
| 2018-07-16 | Iniziato | William Blair | Outperform |
Mostra tutto
Kezar Life Sciences Inc Borsa (KZR) Ultime notizie
What is the dividend policy of Kezar Life Sciences Inc. stockAchieve exceptional returns with expert guidance - jammulinksnews.com
Moving Average Trends for Kezar Life Sciences Inc. Stock: What They IndicateSwing Trade Planning with Consistent Setup - Newser
How to forecast Kezar Life Sciences Inc. trends using time seriesFree Conservative Entry for High Return Setup - Newser
How Kezar Life Sciences Inc. stock reacts to Fed policy changes High Probability Trade Outcome Prediction - Newser
How volatile is Kezar Life Sciences Inc. stock compared to the marketMarket Forecast Entry Points For Smart Trading - jammulinksnews.com
Is Kezar Life Sciences Inc. stock overvalued or undervaluedAchieve breakthrough profits with expert advice - jammulinksnews.com
When is Kezar Life Sciences Inc. stock expected to show significant growthAchieve consistent profits with expert advice - jammulinksnews.com
How Kezar Life Sciences Inc. stock reacts to Fed policy changesStrong Return Daily Alerts - metal.it
How strong is Kezar Life Sciences Inc. company’s balance sheetRapid market gains - jammulinksnews.com
Kezar Life Sciences Inc. Stock Performance After Earnings: Historical InsightsHigh Potential Stock Ideas - Newser
Why Kezar Life Sciences Inc. stock attracts strong analyst attentionInsider Level Guidance - Newser
How Kezar Life Sciences Inc. stock performs during market volatilityHigh Potential Stock Ideas - Newser
What analysts say about Kezar Life Sciences Inc. stockMassive portfolio appreciation - PrintWeekIndia
Kezar Life Sciences Inc. Stock Analysis and ForecastSuperior return velocity - PrintWeekIndia
Is Kezar Life Sciences Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
Should I buy Kezar Life Sciences Inc. stock before earningsRemarkably fast returns - jammulinksnews.com
What drives Kezar Life Sciences Inc. stock priceAccelerated wealth expansion - jammulinksnews.com
When (KZR) Moves Investors should Listen - news.stocktradersdaily.com
Kezar Life Sciences’ (KZR) Neutral Rating Reiterated at HC Wainwright - Defense World
How high can Kezar Life Sciences Inc. stock price go in 2025Chart Based Entries - Newser
HC Wainwright & Co. Maintains Neutral Rating on Kezar Life Sciences - AInvest
In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial - insights.citeline.com
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study - Benzinga
FDA lifts partial hold on Kezar’s zetomipzomib trial - The Pharma Letter
KZR: Kezar Life Sciences Maintains Neutral Rating by HC Wainwrig - GuruFocus
Kezar Says US FDA Lifts Partial Clinical Hold on Zetomipzomib Trial in Autoimmune Hepatitis; Shares Rise After Hours - MarketScreener
Kezar Life Sciences stock gains after FDA lifts partial clinical hold - Investing.com Canada
Kezar Life Sciences Inc Azioni (KZR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kezar Life Sciences Inc Azioni (KZR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schiller Mark C. | Chief Operating Officer |
Jul 02 '25 |
Sale |
4.28 |
561 |
2,401 |
2,739 |
0.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):